Literature DB >> 19078094

A polymyalgia rheumatica-like syndrome as presentation of metastatic cancer.

J E Naschitz1, G Slobodin, D Yeshurun, M Rozenbaum, I Rosner.   

Abstract

A polymyalgia rheumatica-like syndrome is occasionally the first clinical expression of disseminated cancer. Patients admitted to the medical ward of a general hospital during a 10-year period were surveyed for the presence of polymyalgia rheumatica (PMR) in the context of cancer. Five patients were identified with a PMR-like syndrome characterized by prominent systemic symptoms and one or more features dissimilar from PMR, such as a) age of fewer than 50 years, b) only one typical site involved, c) asymmetrical involvement at typical sites, d) additional painful joints, and e) no improvement on 10 mg/d prednisone treatment. There were four men and one woman. The ages ranged from 37 to 84 years. The onset of PMR-like symptoms preceded the initial diagnosis of cancer or of recurrent cancer by 1 to 3 months. On x-ray of the shoulder and pelvic girdles, lytic lesions were observed in one patient. Bone scintigraphy showed pathologic uptake suggestive of metastatic spread, particularly in the symptomatic segments, in all patients. The primary sites of cancer in the five patients were lung (n = 1), kidney (n = 1), colon (n = 2) and unknown (n = 1). Although a search for malignancy may not be justified in patients presenting with typical PMR, the present survey suggests that in patients with atypical PMR-like syndromes, there is significant risk of cancer involving bones and joints. Isotopic bone scan is an appropriate screening test for such a possibility.

Entities:  

Year:  1996        PMID: 19078094     DOI: 10.1097/00124743-199612000-00002

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  5 in total

Review 1.  [S3 guidelines on treatment of polymyalgia rheumatica : Evidence-based guidelines of the German Society of Rheumatology (DGRh), the Austrian Society of Rheumatology and Rehabilitation (ÖGR) and the Swiss Society of Rheumatology (SGT) and participating medical scientific specialist societies and other organizations].

Authors:  F Buttgereit; T Brabant; H Dinges; I Hiemer; M Kaplani; U Kiltz; D Kyburz; A Reißhauer; M Schneider; C Weseloh; C Dejaco
Journal:  Z Rheumatol       Date:  2018-06       Impact factor: 1.372

2.  Association between rheumatic diseases and cancer: results from a clinical practice cohort study.

Authors:  Mattia Bellan; Enrico Boggio; Daniele Sola; Antonello Gibbin; Alessandro Gualerzi; Serena Favretto; Giulia Guaschino; Ramona Bonometti; Roberta Pedrazzoli; Mario Pirisi; Pier Paolo Sainaghi
Journal:  Intern Emerg Med       Date:  2017-02-08       Impact factor: 3.397

3.  Ciliated muconodular papillary tumor of the lung presenting with polymyalgia rheumatica-like symptoms: a case report.

Authors:  Tsuyoshi Uchida; Hirochika Matsubara; Yuuichirou Ohnuki; Aya Sugimura; Hiroyasu Matsuoka; Tomofumi Ichihara; Hiroyuki Nakajima
Journal:  AME Case Rep       Date:  2019-10-11

4.  [This is how I treat-Polymyalgia rheumatica with a cumulative dosage of glucocorticoids as low as possible].

Authors:  Jens Gert Kuipers
Journal:  Z Rheumatol       Date:  2022-01-20       Impact factor: 1.372

5.  Metastatic prostate cancer mimicking polymyalgia rheumatica.

Authors:  Charles T Randazzo; Aaron W Bernard; Douglas A Rund
Journal:  Case Rep Emerg Med       Date:  2011-12-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.